Michael Xu is the founder of Hepagene Therapeutics. Backed by Apricot Capital. Based in Shanghai, China.
Hepagene Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for patients with liver diseases, including non-alcoholic steatohepatitis (NASH) and cholestatic hepatitis. The company is developing HPG1860, a farnesoid X receptor (FXR) agonist, which has progressed to Phase IIa clinical trials for NASH.
Full founder directory · Investor directory · Company funding database · Fundraising library